CFO
TLX

CVA Family Office’s Telix Pharmaceuticals TLX Stock Holding History

CVA Family Office’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46K Hold
127
– – ﹤0.01% 1570
2026
Q1 		$1.22K Buy
+127
New +$967 ﹤0.01% 1619

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

CVA Family Office's TLX Position: Q2 2026 in Review

CVA Family Office held its Telix Pharmaceuticals (TLX) position steady in Q2 2026 at 127 shares worth $1.46K. The position accounts for ﹤0.01% of the portfolio, ranked #1570.

CVA Family Office first reported a position in TLX in Q1 2026 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • CVA Family Office held 127 shares of Telix Pharmaceuticals worth $1.46K as of Q2 2026.
  • CVA Family Office left its Telix Pharmaceuticals share count unchanged in Q2 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1570 holding.
  • CVA Family Office first reported a position in Telix Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.